

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT****Complete if Known**

Application No.	10/813,417
Filing Date	March 30, 2004
First Named Inventor	Po-Ying Chan-Hui
Art Unit	1642
Examiner Name	Laura B. Goddard
Attorney Docket Number	25237-12977

Sheet 1 of 3

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document No. Number – Kind Code ² (if known)	Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
	A1	US-7,135,300	11-14-2006	Chan-Hui et al.
	A2	US-7,105,308	09-12-2006	Chan-Hui et al.
	A3	US-6,770,439	08-03-2004	Singh et al.
	A4	US-6,649,351	11-18-2003	Matray et al.
	A5	US-6,627,400	09-30-2003	Singh et al.
	A6	US-5,470,705	11-28-1995	Grossman et al.
	A7	US-2002/098478 A1	07-25-2002	Wold
	A8	US-2002/045178 A1	04-18-2002	Cantor et al.
	A9	US-2001/049105 A1	12-06-2001	Singh et al.

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ – Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶
	B1	DE 4307736 A1	09-23-1993	Olympus Optical Co., Ltd.	
	B2	WO 03/076649 A1	09-18-2003	Aclara Biosciences, Inc.	
	B3	WO 02/097112 A2	12-05-2002	Aclara Biosciences, Inc.	
	B4	WO 02/083954 A1	10-24-2002	PE Corp (NY)	
	B5	WO 02/29109 A2	04-11-2002	Aclara Biosciences, Inc.	
	B6	WO 00/16087 A1	03-23-2000	The Perkin-Elmer Corporation	
	B7	WO 97/17467 A1	05-15-1997	Pharmacia Biotech AB	

OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
	C1	AUTIERO et al., "Role of PIGF in the Intra- and Intermolecular Cross Talk Between VEGF Receptors Flt1 and Flk1," Nature Medicine, June 8, 2003, pp. 936-943, Vol. 9.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.B.G./

25237/12977/DOCS/1916600.1

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application No.	10/813,417
				Filing Date	March 30, 2004
				First Named Inventor	Po-Ying Chan-Hui
				Art Unit	1642
				Examiner Name	Laura B. Goddard
Sheet	2	of	3	Attorney Docket Number	25237-12977

OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
	C2	BURMER, G.C. et al., "Frequency and Spectrum of c-Ki-ras Mutations in Human Sporadic Colon Carcinoma, Carinomas Arising in Ulcerative Colitis, and Pancreatic Adenocarcinoma, Environmental Health Perspectives, 1991, pp. 27-31, Vol. 93.	
	C3	BUSKEN, C. et al., "Adenocarcinomas of the Gastro-Esophageal Junction: A Comparative Study of the Gastric Cardia and the Esophagus with Respect to Cyclooxygenase-2 Expression," Digestive Disease Week Abstracts and Itinerary Planner, 2003, Abstract No. 850.	
	C4	DREXLER, H.G. et al., "Recent Results on the Biology of Hodgkin and Reed-Sternberg Cells, II. Continuous Cell Lines," Leukemia and Lymphoma, 1993, pp. 1-25, Vol. 9.	
	C5	EMBLETON, M.J. et al., "Monoclonal Antibodies to Osteogenic Sacroma Antigens," Immunol. Ser., 1984, pp. 181-207, Vol. 23.	
	C6	European Examination Report, European Application EP 03771670.1, December 14, 2007, 4 pages.	
	C7	European Examination Report, European Application EP 03771670.1, March 8, 2007, 6 pages.	
	C8	European Search Report, European Application EP 03771670.1, July 18, 2006, 2 pages.	
	C9	European Supplementary Search Report, European Application EP 03815205.4, January 10, 2008, 6 pages.	
	C10	European Supplementary Search Report, European Application EP03746104.3, June 1, 2007, 2 pages.	
	C11	HSU, T.C., "Karyology of Cells in Culture," Tissue Culture Methods and Applications, Kruse and Patterson, Eds., Academic Press, N.Y., 1973, p. 764.	
	C12	KUNKEL, P. et al., "Expression and Localization of Scatter Factor/ Hepatocyte Growth Factor in Human Astrocytomas," Neuro-Oncology, April 2001, pp. 82-88, Vol. 3, No. 2.	
	C13	MONTESANO, R. et al., "Genetic Alterations in Esophageal Cancer and Their Relevance to Etiology and Pathogenesis: A Review," Intl. J. Cancer, 1996, pp. 225-235, Vol. 69, No. 3.	
	C14	RIOS, C.D. et al., "G-Protein-Coupled Receptor Dimerization: Modulation of Receptor Function," Pharmacology and Therapeutics, November 2001, pp. 71-87, Vol. 92, No. 2/3.	
	C15	TIAN, J. et al., "The Expression of Native and Cultured RPE Grown on Difference Matrices," Physiol. Genomics, February 24, 2004, pp. 170-182, Vol. 17.	
	C16	TOCKMAN, M.S. et al., "Considerations in Bringing a Cancer Biomarker to Clinical Application," Cancer Research, May 1, 1992, pp. 2711s-2718s, Vol. 52.	
	C17	VAN DYKE, D. et al., "Monosomy 21 in Hematologic Diseases," Cancer Genetics and Cytogenetics, 2003, pp. 137-141, Vol. 241.	
	C18	WATHELET, M. et al., "Electrophereogram Comparison by Computer," Chemometrics and Intelligent Laboratory Systems, 1998, pp. 327-339, Vol. 4.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.B.G./ 25237/12977/DQCS/1916600.1

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT****Complete if Known**

Application No.	10/813,417
Filing Date	March 30, 2004
First Named Inventor	Po-Ying Chan-Hui
Art Unit	1642
Examiner Name	Laura B. Goddard
Attorney Docket Number	25237-12977

Sheet	3	of	3
-------	---	----	---

OTHER REFERENCES – NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ⁶
	C19	WHITAKER, G.B. et al., "Vascular Endothelial Growth Factor Receptor-2 and Neuropilin-1 Form a Receptor Complex That Is Responsible for the Differential Signaling Potency of VEGF ₁₆₅ and VEGF ₁₂₁ ," The Journal of Biological Chemistry, July 6, 2001, pp. 25520-25531, Vol. 276.	
	C20	WILDI, S. et al., "Overexpression of Activin A in Stage IV Colorectal Cancer," Gut Online, September 2001, pp. 409-471, Vol. 49.	
	C21	YAKES, F.M. et al., "Herceptin-Induced Inhibition of Phosphatidylinositol-3 Kinase and Akt is Required for Antibody-mediated Effects on p27, Cyclin D1, and Antitumor Action," Cancer Research, July 15, 2002, pp. 4132-4141, Vol. 62.	
	C22	ZASLAV, A.L. et al., "Significance of a Prenatally Diagnosed del(10)(q23)," American Journal of Medical Genetics, 2002, pp. 174-176, Vol. 107.	

Examiner Signature	/Laura B. Goddard/	Date Considered	06/23/2008
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.B.G./

25237/12977/DOCS/1916600.1